PMC:7556165 / 56765-57794 JSONTXT

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T170","span":{"begin":918,"end":929},"obj":"Chemical"}],"attributes":[{"id":"A170","pred":"chebi_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T341","span":{"begin":21,"end":31},"obj":"Species"},{"id":"T342","span":{"begin":21,"end":25},"obj":"Species"}],"attributes":[{"id":"A341","pred":"ncbi_taxonomy_id","subj":"T341","obj":"NCBItxid:2697049"},{"id":"A342","pred":"ncbi_taxonomy_id","subj":"T342","obj":"NCBItxid:694009"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T350","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T351","span":{"begin":171,"end":639},"obj":"Sentence"},{"id":"T352","span":{"begin":640,"end":1029},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1581","span":{"begin":900,"end":903},"obj":"Gene"},{"id":"1582","span":{"begin":21,"end":31},"obj":"Species"},{"id":"1583","span":{"begin":951,"end":959},"obj":"Species"},{"id":"1584","span":{"begin":970,"end":982},"obj":"Disease"},{"id":"1585","span":{"begin":1007,"end":1028},"obj":"Disease"}],"attributes":[{"id":"A1581","pred":"pubann:denotes","subj":"1581","obj":"Gene:1636"},{"id":"A1582","pred":"pubann:denotes","subj":"1582","obj":"Tax:2697049"},{"id":"A1583","pred":"pubann:denotes","subj":"1583","obj":"Tax:9606"},{"id":"A1584","pred":"pubann:denotes","subj":"1584","obj":"MESH:D006973"},{"id":"A1585","pred":"pubann:denotes","subj":"1585","obj":"MESH:D018352"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T5736","span":{"begin":900,"end":903},"obj":"Protein"},{"id":"T5761","span":{"begin":918,"end":929},"obj":"Protein"}],"attributes":[{"id":"A5736","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q9GLN7"},{"id":"A5737","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q9GLN6"},{"id":"A5738","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q9EQM9"},{"id":"A5739","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q8CFN1"},{"id":"A5740","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q7TMC6"},{"id":"A5741","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q7M4L4"},{"id":"A5742","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q6GTS2"},{"id":"A5743","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q59GY8"},{"id":"A5744","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q53YX9"},{"id":"A5745","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q50JE5"},{"id":"A5746","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q10751"},{"id":"A5747","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q0GA41"},{"id":"A5748","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P47820"},{"id":"A5749","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P22968"},{"id":"A5750","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P22967"},{"id":"A5751","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P22966"},{"id":"A5752","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P12822"},{"id":"A5753","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P12821"},{"id":"A5754","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P12820"},{"id":"A5755","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/P09470"},{"id":"A5756","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/O02852"},{"id":"A5757","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/E7EU16"},{"id":"A5758","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/B4DXI3"},{"id":"A5759","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/B0LPF0"},{"id":"A5760","pred":"uniprot_id","subj":"T5736","obj":"https://www.uniprot.org/uniprot/Q9VJV3"},{"id":"A5761","pred":"uniprot_id","subj":"T5761","obj":"https://www.uniprot.org/uniprot/Q10757"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T218","span":{"begin":1019,"end":1028},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T322","span":{"begin":21,"end":31},"obj":"Disease"},{"id":"T323","span":{"begin":21,"end":25},"obj":"Disease"},{"id":"T324","span":{"begin":90,"end":93},"obj":"Disease"},{"id":"T325","span":{"begin":449,"end":453},"obj":"Disease"},{"id":"T326","span":{"begin":740,"end":743},"obj":"Disease"},{"id":"T327","span":{"begin":970,"end":982},"obj":"Disease"},{"id":"T328","span":{"begin":1019,"end":1028},"obj":"Disease"}],"attributes":[{"id":"A322","pred":"mondo_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A323","pred":"mondo_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A324","pred":"mondo_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A325","pred":"mondo_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/MONDO_0008199"},{"id":"A326","pred":"mondo_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A327","pred":"mondo_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A328","pred":"mondo_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T56","span":{"begin":970,"end":982},"obj":"Phenotype"}],"attributes":[{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T59","span":{"begin":970,"end":982},"obj":"Phenotype"}],"attributes":[{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1581","span":{"begin":900,"end":903},"obj":"Gene"},{"id":"1582","span":{"begin":21,"end":31},"obj":"Species"},{"id":"1583","span":{"begin":951,"end":959},"obj":"Species"},{"id":"1584","span":{"begin":970,"end":982},"obj":"Disease"},{"id":"1585","span":{"begin":1007,"end":1028},"obj":"Disease"}],"attributes":[{"id":"A1581","pred":"tao:has_database_id","subj":"1581","obj":"Gene:1636"},{"id":"A1582","pred":"tao:has_database_id","subj":"1582","obj":"Tax:2697049"},{"id":"A1583","pred":"tao:has_database_id","subj":"1583","obj":"Tax:9606"},{"id":"A1584","pred":"tao:has_database_id","subj":"1584","obj":"MESH:D006973"},{"id":"A1585","pred":"tao:has_database_id","subj":"1585","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T350","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T351","span":{"begin":171,"end":639},"obj":"Sentence"},{"id":"T352","span":{"begin":640,"end":1029},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Hence, following the SARS-CoV-2 outbreak, it has been speculated that the use of ACEI and ARB could increase viral invasion and should therefore be temporarily suspended. This topic has been abundantly debated in the last few months (March–May 2020), with contradictory views (Bavishi et al., 2020; Buckley et al., 2020; Danser et al., 2020; Fang et al., 2020; Huang Z. et al., 2020; Kreutz et al., 2020; Kuster et al., 2020; Mourad and Levy, 2020; Park et al., 2020; Rico-Mesa et al., 2020; Sommerstein et al., 2020; South et al., 2020; Tignanelli et al., 2020; Vaduganathan et al., 2020; Verdecchia et al., 2020b; Zhang P. et al., 2020). As a consequence of this debate, several clinical societies have stated that suspension of ACEI and ARB is not justified on the basis of the present scientific evidence, although a recent BMJ editorial (Aronson and Ferner, 2020) suggested to consider stopping ACE inhibitors or angiotensin receptor blockers in patients with mild hypertension who are at high risk of coronavirus infection."}